The Efficacy of AR101, a Peanut-Derived Pharmaceutical for Oral Immunotherapy (OIT), Is Maintained and Tolerability Is Increased with Low-Dose Maintenance Therapy
Published in
The Journal of Allergy and Clinical Immunology, February 2016
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 March 2016.
All research outputs
#9,676,677
of 34,559,526 outputs
Outputs from The Journal of Allergy and Clinical Immunology
#8,170
of 14,623 outputs
Outputs of similar age
#117,104
of 453,467 outputs
Outputs of similar age from The Journal of Allergy and Clinical Immunology
#106
of 204 outputs
Altmetric has tracked 34,559,526 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 14,623 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.2. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 453,467 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 204 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
